×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALEC – alector, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALEC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/3
09:59 pm
alec
Alector Showcases ABC Brain-Delivery Platform, AL137 and AL050 Updates at TD Cowen Conference [Yahoo! Finance]
Medium
Report
Alector Showcases ABC Brain-Delivery Platform, AL137 and AL050 Updates at TD Cowen Conference [Yahoo! Finance]
3/1
01:10 am
alec
Alector (ALEC) was downgraded by Wall Street Zen from "hold" to "sell
High
Report
Alector (ALEC) was downgraded by Wall Street Zen from "hold" to "sell
2/25
04:05 pm
alec
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/24
08:00 am
alec
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
1/29
06:06 pm
alec
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint
Low
Report
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint
1/8
08:42 am
alec
Alector (NASDAQ:ALEC) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Alector (NASDAQ:ALEC) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
12/16
04:14 pm
alec
Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst [Seeking Alpha]
Low
Report
Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst [Seeking Alpha]
12/15
07:31 am
alec
Earnings calls citing ‘AI' surge in 2025 as ‘uncertainty' mentions fade [Fortune]
Medium
Report
Earnings calls citing ‘AI' surge in 2025 as ‘uncertainty' mentions fade [Fortune]
Date
Time
Symbol
Headline
Impact
3/3
06:01 pm
alec
Form 4 Alector, Inc. For: Mar 03 Filed by: Wong-Sarad Grace
Medium
Report
Form 4 Alector, Inc. For: Mar 03 Filed by: Wong-Sarad Grace
3/3
05:09 pm
alec
Form 144 Alector, Inc. Filed by: Wong-Sarad Grace
Medium
Report
Form 144 Alector, Inc. Filed by: Wong-Sarad Grace
3/3
04:07 pm
alec
Form 4 Alector, Inc. For: Mar 02 Filed by: Wong-Sarad Grace
Low
Report
Form 4 Alector, Inc. For: Mar 02 Filed by: Wong-Sarad Grace
3/3
04:06 pm
alec
Form 4 Alector, Inc. For: Mar 02 Filed by: Rosenthal Arnon
Low
Report
Form 4 Alector, Inc. For: Mar 02 Filed by: Rosenthal Arnon
3/3
04:05 pm
alec
Form 4 Alector, Inc. For: Mar 02 Filed by: Berkley Neil Lindsay
Low
Report
Form 4 Alector, Inc. For: Mar 02 Filed by: Berkley Neil Lindsay
2/27
06:11 pm
alec
Form 144 Alector, Inc. Filed by: Rosenthal Arnon
Medium
Report
Form 144 Alector, Inc. Filed by: Rosenthal Arnon
2/27
06:11 pm
alec
Form 144 Alector, Inc. Filed by: Wong-Sarad Grace
Medium
Report
Form 144 Alector, Inc. Filed by: Wong-Sarad Grace
2/27
06:11 pm
alec
Form 144 Alector, Inc. Filed by: Berkley Neil Lindsay
Medium
Report
Form 144 Alector, Inc. Filed by: Berkley Neil Lindsay
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/5
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia
12.0%
1/30 Form EFFECT Alector, Inc. 10.9%
1/8 Alector to Present at the J.P. Morgan 38th Annual Healthcare Conference 10.0%
4/28 Alector Inc (NASDAQ: ALEC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%
4/17 Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC 8.0%
2/3 Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 7.1%
5/13 Q1/2019 3/31/2019 EPS -0.420 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%
3/25 Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China 5.5%
9/9 Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia 4.7%
12/11 Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer 4.3%
1/30 Form EFFECT Alector, Inc. 10.9%
1/8 Alector to Present at the J.P. Morgan 38th Annual Healthcare Conference 10.0%
4/28 Alector Inc (NASDAQ: ALEC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%
4/17 Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC 8.0%
2/3 Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 7.1%
5/13 Q1/2019 3/31/2019 EPS -0.420 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%
3/25 Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China 5.5%
9/9 Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia 4.7%
12/11 Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer 4.3%
TOP News Decliners
3/30
Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC
-22.2%
2/7 Form 4 Alector, Inc. For: Feb 05 Filed by: Paul Robert -19.8%
3/23 Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors -18.8%
3/17 Alector Inc (NASDAQ: ALEC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. -11.1%
2/24 Alector to Present at the Cowen 40th Annual Health Care Conference -11.0%
4/2 Form 4 Alector, Inc. For: Mar 31 Filed by: ORBIMED ADVISORS LLC -8.8%
4/9 Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC -8.0%
12/8 Alector Inc (NASDAQ: ALEC) had its "buy" rating re-affirmed by analysts at Cowen Inc. -6.2%
3/4 Form 4 Alector, Inc. For: Mar 02 Filed by: OrbiMed Capital GP IV LLC -6.0%
1/27 Alector Announces Proposed Public Offering of Common Stock -5.4%
2/7 Form 4 Alector, Inc. For: Feb 05 Filed by: Paul Robert -19.8%
3/23 Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors -18.8%
3/17 Alector Inc (NASDAQ: ALEC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. -11.1%
2/24 Alector to Present at the Cowen 40th Annual Health Care Conference -11.0%
4/2 Form 4 Alector, Inc. For: Mar 31 Filed by: ORBIMED ADVISORS LLC -8.8%
4/9 Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC -8.0%
12/8 Alector Inc (NASDAQ: ALEC) had its "buy" rating re-affirmed by analysts at Cowen Inc. -6.2%
3/4 Form 4 Alector, Inc. For: Mar 02 Filed by: OrbiMed Capital GP IV LLC -6.0%
1/27 Alector Announces Proposed Public Offering of Common Stock -5.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: